Influenza

Pivotal Phase III Trial of Intranasal Influenza Vaccine Initiated

Published in Vaccine Weekly, September 9th, 1996

Aviron, Mountain View, California, announced the initiation of pivotal Phase III trials of the company's lead product - the most advanced intranasal influenza vaccine currently in clinical trials - designed to prevent influenza virus related disease.

The intranasal influenza vaccine is tested in a randomized double-blind placebo-controlled study in more than 900 children aged 15 through 71 months of age in a multi-center trial in collaboration with the U.S. National Institute of Allergy and Infectious Disease (NIAID), of the U.S. National Institutes of Health (NIH), with whom Aviron has entered into a Collaborative Research and Development Agreement (CRADA) in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1996-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry